Amygdala Neuroscience
Amygdala Neuroscience is a free online portal to create group projects and media item related to neuroscience.
About Amygdala Neuroscience
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies. Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.
Company Facts
- Headquarters
- Palo Alto
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00001_00010
- Total Funding
- $8,950,000
- Last Funding Type
- grant
- Last Funding Date
- 2024-05-14
- Website
- amygns.com
Industries & Categories
Addiction Treatment, Biotechnology, Health Care, Neuroscience, Online Portals, Pharmaceutical
Social Links
Canonical: https://fsome.com/organization/amygdala-neuroscience-95877 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.